Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the publication of new data from a retrospective investigator-initiated study analyzing the use of EXPAREL (bupivacaine liposome injectable suspension) administered as a transversus abdominis plane (TAP) block to manage postsurgical pain following cesarean section (C-section) procedures.
Findings show that patients receiving EXPAREL had a significant reduction in opioid consumption and pain intensity, as well as significantly improved discharge- and postanesthesia care unit (PACU)-ready times, functional recovery and reduced length of stay (LOS). The study results were published this week in The Journal of Pain Research.
Study researchers reviewed the charts of 201 consecutive women who underwent C-section procedures and received a multimodal pain management protocol with or without a TAP block utilizing 266 mg of EXPAREL. The study population included patients who underwent elective, unscheduled waiting list, or emergency cesarean delivery with anesthesia and post-cesarean pain management by one anesthesiologist at Texas Children’s Hospital Pavilion for Women between 2012 and 2015.
Compared to patients who received multimodal pain control without the use of EXPAREL, patients who received a TAP block demonstrated a statistically significant: Decrease in postsurgical opioid consumption by 47%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.